SynthesisInternational journal of chronic obstructive pulmonary disease2025
Respiratory Muscle Strength and Mortality in Patients with COPD: A Systematic Review and Meta-Analysis.
Synthesis in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Purpose: Respiratory muscle weakness is common in chronic obstructive pulmonary disease (COPD), potentially carrying prognostic information beyond airflow limitation; however, clinical testing remains variably standardized, and its independent association with survival is uncertain. We evaluated whether respiratory muscle strength is associated with survival in patients with COPD, and summarized implementation-relevant evidence for other indices. Methods: We systematically searched PubMed/MEDLINE, CENTRAL, and Web of Science from January 1, 1990 to September 30, 2025, screened observational cohorts and baseline-prognosis analyses in patients with COPD, appraised risk of bias, and meta-analyzed time-to-event estimates using random-effects where ≥2 comparable studies were available. Eligible studies enrolled patients with COPD with observational cohorts or baseline-prognosis analyses reporting all-cause mortality as outcome. Results: Of the six eligible studies, two permitted pooling for inspiratory strength versus all-cause mortality. Lower inspiratory strength was associated with higher mortality (pooled hazard ratio 0.97, 95% confidence interval 0.95-0.99; I Conclusion: MIP shows a consistent directional association with survival in patients with COPD, although magnitude estimates vary with measurement protocols and confounder control. We propose a minimum reporting set (posture, starting lung volume, trials/repeatability, device/calibration, cmH
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.